Pamela Bradt, ICER CSO

ICER crit­i­cizes cost of 8 tar­get­ed im­mune mod­u­la­tors for UC, rec­om­mend­ing some deep dis­counts

While 8 tar­get­ed im­mune mod­u­la­tors (TIMs) on the mar­ket for ul­cer­a­tive col­i­tis have proved ben­e­fi­cial to pa­tients, non­prof­it cost-ef­fec­tive­ness watch­dog ICER called the drugs un­rea­son­ably ex­pen­sive, rec­om­mend­ing some deep dis­counts to match the drugs with their ac­tu­al val­ue.

In a re­port re­leased Fri­day, ICER as­sessed the cost vs. clin­i­cal ben­e­fit of mar­ket leader Hu­mi­ra — for which Ab­b­Vie has faced price goug­ing ac­cu­sa­tions — as well as Janssen’s Sim­poni, Ste­lara and Rem­i­cade, Mer­ck’s Ren­flex­is, Pfiz­er’s In­flec­tra and Xel­janz, and Take­da’s En­tyvio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.